Lupin gets warning letter from US FDA for Somerset facility

Lupin has received a warning letter from the US FDA for the company’s Somerset, New Jersey facility. The US FDA had inspected the Lupin Somerset site from September 10, 2020, to November 5, 2020.

A statement from Lupin informed, “The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility. We are committed to addressing the concerns raised by the US FDA and will work with the FDA and the New Jersey District to resolve these issues at the earliest.”